Clinical trial
Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
NCT00108758 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Exploratory, Multi-centre, Randomised, Double-blind, Uncontrolled Trial Evaluating the Efficacy of Activated Recombinant Factor VII (rFVIIa/NovoSeven®) in Secondary Bleeding Prophylaxis in Congenital Haemophilia A or B Patients With Inhibitors
- Lead sponsor
- Novo Nordisk A/S
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2004
- Completion date
- November 30, 2005
- Enrollment
- 23 (actual)
- Sites
- 37
Conditions
As the registry lists them; a condition with its own page is linked.
congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors